TGFB1 and breast carcinoma: One of the breast cancer patients in the present cohort had exceptionally high levels of LAP in CD4+ T cells (Figure 2B), but overall there was no significant difference in LAP expression between NILs (1.7 ± 1.4%) and TILs (4.5 ± 3.5%; Figure 2A and 2C).